How does valerenic acid make you sleepy?

Valerenic acid promotes sedation by allosterically modulating GABA-A receptors in the central nervous system, enhancing the effects of the inhibitory neurotransmitter GABA and reducing neuronal excitability in a manner broadly analogous to, but mechanistically distinct from, benzodiazepines. This GABAergic activity is considered the primary molecular basis for the traditional and clinical use of valerian root extracts — in which valerenic acid serves as the key standardization marker — for insomnia and anxiety, though human studies have been conducted on whole valerian extracts rather than isolated valerenic acid.

What is a standard dose of valerenic acid in valerian supplements?

No human clinical dosing regimen has been established for isolated valerenic acid; supplemental exposure is typically calculated from standardized valerian root extract doses. Commercial preparations standardized to 0.8–1% valerenic acid at a 300–600 mg extract dose deliver approximately 2.4–6 mg of valerenic acid per serving, generally taken 30–60 minutes before sleep, though these figures are derived from product standardization conventions rather than dose-finding clinical trials for the isolated compound.

Is valerenic acid the same as valerian root?

Valerenic acid is not the same as valerian root; it is one specific sesquiterpenoid compound isolated from the roots and rhizomes of Valeriana officinalis L., the valerian plant. Valerian root contains a complex mixture of bioactive constituents including acetoxyvalerenic acid, hydroxyvalerenic acid, valerenal, bornyl acetate, α-humulene, and phenolic acids, but valerenic acid is used as the primary chemical marker for extract standardization because of its stability and well-characterized anxiolytic mechanism.

What receptors does valerenic acid act on?

Valerenic acid acts on at least two receptor systems: it allosterically modulates GABA-A receptors in the central nervous system, enhancing inhibitory neurotransmission to produce anxiolytic and sedative effects, and it selectively activates retinoid X receptor β (RXRβ) in nuclear receptor signaling with an EC₅₀ of 5 µM and 69-fold activation. Notably, valerenic acid does not meaningfully activate retinoic acid receptors, peroxisome proliferator-activated receptors, liver X receptors, or farnesoid X receptor, indicating a selective nuclear receptor profile that limits potential off-target endocrine effects.

How much valerenic acid is actually in a valerian root supplement?

Valerenic acid content varies significantly between valerian supplements, typically ranging from 0.3% to 0.7% by weight in standardized extracts, while whole root powders may contain as little as 0.1%. Most clinical studies use extracts standardized to 0.4–0.8% valerenic acid to ensure consistent dosing. Always check the supplement label for the percentage of valerenic acid or total valerian extract to understand what you're actually consuming.

Is valerenic acid safe for children or elderly people?

Safety data for valerenic acid in children under 12 is limited, and use in this population is generally not recommended without pediatric medical guidance. In elderly individuals, valerenic acid appears to be reasonably well-tolerated, though older adults may be more sensitive to sedative effects and should start with lower doses to assess tolerance. Anyone in these populations should consult a healthcare provider before supplementing.

What does research show about how effective valerenic acid is compared to pharmaceutical sleep aids?

Clinical studies suggest valerenic acid improves sleep quality and latency, but effects are generally more modest and slower-acting than prescription benzodiazepines or sleep medications. Most research shows meaningful benefit emerges after 2–4 weeks of consistent use, whereas pharmaceuticals often produce immediate effects. While valerenic acid carries lower dependency risk, it is not a direct replacement for prescription sleep medications and works best for mild to moderate sleep disturbances.

Valerenic Acid

Valerenic acid is the principal sesquiterpenoid bioactive marker of Valeriana officinalis, exerting anxiolytic and sedative effects primarily through modulation of GABA receptors and selective activation of retinoid X receptor β (RXRβ) at an EC₅₀ of 5 µM with 69-fold receptor activation. Preclinical pharmacokinetic studies in rats demonstrate oral bioavailability of 33.7% with a biphasic elimination profile (t½ elimination up to 46 hours), and in vitro data show meaningful enzyme inhibition of ACE (IC₅₀ ≈ 0.225 mg/mL) and α-glucosidase (IC₅₀ ≈ 0.617 mg/mL), though robust human clinical trial data specific to isolated valerenic acid remain limited.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Valerenic acid is a sesquiterpenoid terpenoid isolated primarily from the roots and rhizomes of Valeriana officinalis L. (common valerian), a perennial herb native to Europe and Asia and widely naturalized in North America. The plant thrives in moist, well-drained soils at moderate altitudes and has been cultivated for centuries across Poland, Germany, the Netherlands, and the Baltic regions for its medicinal root material. Valerenic acid concentrations vary significantly by cultivar, plant part, harvest timing, and post-harvest processing, with rhizomes generally yielding higher concentrations than lateral roots.

Historical & Cultural Context

Valeriana officinalis has been documented as a medicinal plant since ancient Greek and Roman antiquity, with Dioscorides and Galen referencing its use as a remedy for epilepsy, insomnia, and nervous agitation in the first and second centuries CE. In medieval European herbalism, valerian root (then called 'phu' or 'setwall') was a prominent remedy in monastic pharmacopoeias, used to calm the nervous system and promote sleep, predating by millennia the identification of valerenic acid as its principal bioactive constituent. The plant held official pharmacopoeial status in numerous European countries through the 18th and 19th centuries, including the British, German, and Swiss pharmacopoeias, where root preparations were standardized empirically long before chromatographic methods enabled quantification of valerenic acid. The isolation and structural characterization of valerenic acid as a discrete sesquiterpenoid in the 20th century provided the first molecular basis for explaining these centuries of traditional use, transforming valerian from a folk remedy into a subject of modern pharmacological investigation.

Health Benefits

- **Anxiolytic Activity**: Valerenic acid modulates GABAergic signaling by acting on GABA-A receptor subunits, reducing neuronal excitability in a manner analogous to benzodiazepines but with a distinct binding profile, contributing to measurable reductions in anxiety-like behavior in preclinical models.
- **Sleep and Sedation Support**: As the primary bioactive marker in valerian root extracts used clinically for insomnia, valerenic acid's GABAergic mechanism underpins the sedative effects of standardized valerian preparations, with commercial extracts typically standardized to 0.8–1% valerenic acid content.
- **Retinoid X Receptor Modulation**: Valerenic acid selectively activates RXRβ with an EC₅₀ of 5 µM (69-fold activation), far exceeding its activity at RXRα (EC₅₀ 27 µM, 9-fold) and RXRγ (EC₅₀ 43 µM, 4-fold), suggesting roles in nuclear receptor signaling pathways relevant to metabolism and neuroprotection.
- **ACE Inhibition (Antihypertensive Potential)**: In vitro studies demonstrate that valerenic acid inhibits angiotensin-converting enzyme (ACE) with an IC₅₀ of approximately 0.225 mg/mL, indicating a potential adjunctive role in cardiovascular risk management, though human validation is absent.
- **α-Glucosidase Inhibition (Antidiabetic Potential)**: Valerenic acid inhibits α-glucosidase with an IC₅₀ of approximately 0.617 mg/mL in vitro, outperforming some phenolic acids and suggesting utility in attenuating postprandial glucose absorption, pending clinical confirmation.
- **Metabolic Syndrome Enzyme Inhibition**: Valerian extracts rich in valerenic acid also inhibit lipase and α-amylase in vitro, targeting multiple enzymatic pathways implicated in obesity and type 2 diabetes, positioning valerenic acid as a potential multi-target agent for metabolic syndrome components.
- **Neuroprotective and Receptor Selectivity Profile**: The compound's lack of activity at RARs, PPARs, LXRs, and FXR despite strong RXRβ selectivity suggests a focused mechanism that may limit off-target metabolic or endocrine disruption, a favorable characteristic for CNS-targeted therapeutic development.

How It Works

Valerenic acid exerts its anxiolytic and sedative effects primarily through allosteric modulation of γ-aminobutyric acid type A (GABA-A) receptors, enhancing inhibitory neurotransmission in the central nervous system in a manner that reduces neuronal hyperexcitability without the full agonist activity associated with benzodiazepines. At the nuclear receptor level, valerenic acid acts as a selective agonist of retinoid X receptor β (RXRβ), achieving 69-fold receptor activation at an EC₅₀ of 5 µM, while demonstrating substantially weaker activity at RXRα (EC₅₀ 27 µM) and RXRγ (EC₅₀ 43 µM), and no appreciable activity at retinoic acid receptors, peroxisome proliferator-activated receptors, liver X receptors, or farnesoid X receptor. Peripheral enzymatic inhibition of ACE (IC₅₀ ≈ 0.225 mg/mL), α-glucosidase (IC₅₀ ≈ 0.617 mg/mL), lipase, and α-amylase has been characterized in vitro, suggesting additional metabolic mechanisms beyond classical CNS targets. The compound's large apparent volume of distribution (Vd 17–20 L/kg in rats) indicates extensive tissue binding, which may contribute to its prolonged elimination half-life of up to 46 hours and sustained pharmacodynamic effects.

Scientific Research

The evidence base for isolated valerenic acid is predominantly preclinical, consisting of in vitro receptor binding and enzyme inhibition assays, pharmacokinetic studies in rodents, and phytochemical characterization studies; no published Phase II or Phase III human clinical trials isolating valerenic acid as the sole intervention have been identified in the available literature. Pharmacokinetic characterization in rats has established a two-compartment model with oral bioavailability of 33.7%, distribution half-life of 6–12 minutes, elimination half-life of 6–46 hours, clearance of 2–5 L·h⁻¹·kg⁻¹, and linear pharmacokinetics across tested dose ranges, providing a foundation for future human PK modeling. Clinical trial data on insomnia and anxiety predominantly pertain to standardized whole valerian root extracts (in which valerenic acid is a key marker) rather than to the isolated compound, making it difficult to attribute observed clinical outcomes directly and exclusively to valerenic acid. The overall evidence for isolated valerenic acid remains at the preclinical stage, with significant gaps in human safety, efficacy, optimal dosing, and long-term tolerability data that must be addressed before clinical recommendations can be made.

Clinical Summary

Human clinical evidence specific to isolated valerenic acid is absent from the published literature; existing clinical data derive from trials using standardized Valeriana officinalis root extracts in which valerenic acid serves as a quantitative marker (typically 0.8–1% content) rather than as the sole active agent. Preclinical pharmacokinetic studies in rats provide the most quantitatively rigorous compound-specific data, demonstrating 33.7% oral bioavailability and a prolonged elimination phase (t½ up to 46 h), which informs hypotheses about tissue accumulation and dosing intervals but cannot be directly extrapolated to humans without bridging studies. In vitro mechanistic studies confirm GABA-A receptor modulation, selective RXRβ agonism, and multi-enzyme inhibition with quantified EC₅₀ and IC₅₀ values, establishing plausible mechanisms for the anxiolytic, sedative, and metabolic effects historically attributed to valerian preparations. Confidence in clinical outcomes attributable specifically to valerenic acid is low given the absence of isolated-compound human trials; practitioners and formulators should regard current evidence as hypothesis-generating rather than practice-defining.

Nutritional Profile

Valerenic acid is a bicyclic sesquiterpenoid (molecular formula C₁₅H₂₂O₂, MW 234.33 g/mol) and is not a macronutrient or micronutrient; it contributes negligibly to caloric or nutritional intake at supplemental concentrations. Within the whole valerian root matrix, valerenic acid co-occurs with its derivatives acetoxyvalerenic acid and hydroxyvalerenic acid (total valerenic acids: 0.12%–2.4 mg/g dry weight depending on cultivar and extraction method), the sesquiterpene aldehyde valerenal, the monoterpene bornyl acetate (up to 15.42% of essential oil fraction), α-humulene, and various phenolic acids including chlorogenic and caffeic acid derivatives. Bioavailability of valerenic acid from oral preparations is estimated at 33.7% in rats based on two-compartment pharmacokinetic modeling, with a large apparent volume of distribution (17–20 L/kg) indicating extensive tissue partitioning; human bioavailability data are unavailable. The rhizome is consistently richer in valerenic acid derivatives than lateral roots, and microwave-assisted drying of harvested material preserves higher biochemical content compared to conventional air drying.

Preparation & Dosage

- **Standardized Valerian Root Extract (Oral Capsule/Tablet)**: Commercial preparations are typically standardized to 0.8–1% valerenic acid content; common valerian extract doses range from 300–600 mg per serving, taken 30–60 minutes before sleep for insomnia applications, implying approximately 2.4–6 mg valerenic acid per dose.
- **70% Ethanol Percolation Extract**: Percolation of valerian rhizomes with 70% ethanol (5:1 herb-to-solvent ratio) yields approximately 2.4 mg/g total valerenic acids, representing an efficient extraction method for standardized liquid extracts and tinctures.
- **Supercritical CO₂ Extract (with 5% Ethanol Modifier)**: Extraction at 10–20 MPa, 40–50°C for 30 minutes with a 5% ethanol or methanol modifier yields 2.4–2.5 mg/g total valerenic acids, comparable to ethanol percolation and preferred for solvent-free standardized extracts.
- **Hot 95% Ethanol Extract (75°C)**: High-temperature ethanol extraction from rhizomes maximizes acetoxyvalerenic acid derivatives (up to 24.2 mg/g, representing 72.85% of total valerenic derivatives), suitable for high-potency formulations.
- **Traditional Aqueous Infusion/Decoction**: Ground dried valerian root prepared as a tea or decoction represents the historical preparation method, though valerenic acid extraction efficiency is lower than ethanol or CO₂ methods and content is not standardized.
- **Standardization Note**: No isolated valerenic acid dosing regimen has been established in human clinical trials; all dose recommendations derive from extracts where valerenic acid is a marker, not the sole quantified active ingredient.
- **Timing**: Extract-based preparations are conventionally consumed in the evening given their sedative mechanism; the long elimination half-life (up to 46 h in rats) suggests potential for accumulation with repeated daily dosing.

Synergy & Pairings

Valerenic acid is most commonly co-formulated with other GABAergic or sedative botanical compounds, particularly lemon balm (Melissa officinalis, providing rosmarinic acid), passionflower (Passiflora incarnata, providing chrysin and orientin), and hops (Humulus lupulus, providing 2-methyl-3-buten-2-ol), creating additive or potentially synergistic inhibitory neurotransmission effects through complementary receptor subtypes and enzyme targets. The combination of valerenic acid's RXRβ agonism with omega-3 fatty acids (which are known RXR ligand modulators and membrane fluidity regulators) has been proposed as a mechanistically rational stack for neuroprotective applications, though direct combinatorial human data are lacking. In metabolic formulations, pairing valerenic acid's α-glucosidase and ACE inhibitory activity with berberine (a direct AMPK activator and α-glucosidase inhibitor) or quercetin (a lipase and ACE inhibitor) could produce complementary multi-enzyme inhibition across overlapping metabolic syndrome pathways, though this combination has not been studied clinically.

Safety & Interactions

Human safety data specific to isolated valerenic acid are absent from the published literature; safety inferences are drawn from preclinical pharmacokinetics and the broader valerian extract literature, where standardized preparations are generally regarded as well-tolerated at recommended doses with occasional reports of headache, gastrointestinal upset, dizziness, and paradoxical excitation. The long elimination half-life observed in rats (up to 46 hours) and the large volume of distribution (17–20 L/kg) raise theoretical concerns about tissue accumulation with chronic daily dosing, particularly in individuals with hepatic or renal impairment who may have reduced clearance capacity. Valerenic acid's GABAergic mechanism introduces a clinically meaningful potential for pharmacodynamic interactions with CNS depressants including benzodiazepines, barbiturates, opioids, alcohol, and other sedative-hypnotic agents, potentially producing additive or synergistic central nervous system depression. Valerian preparations are generally not recommended during pregnancy or lactation due to insufficient safety data; individuals taking cytochrome P450-metabolized medications should exercise caution, as sesquiterpenoid compounds may influence hepatic drug metabolism pathways, though specific CYP interaction profiling for isolated valerenic acid has not been published.